Actinium Pharma (ATNM) Short-Term Debt to Equity

This price chart for Actinium Pharmaceuticals (ATNM) demonstrates the dynamics of a company leading the development of targeted radiotherapy, where the drug Iomab-B simplifies bone marrow transplants for elderly patients. The current metric stands at 0.02, while the business actively conducts final clinical trials of its breakthrough radioconjugates. This biopharmaceutical behemoth is directing colossal funds into R&D, possessing exceptional scientific potential to combat oncohematology.

To build a defensive portfolio, fundamental screening requires an analysis of the ratio of short-term liabilities to equity, which allows for an assessment of a company's reliance on short-term borrowing relative to its net assets. In the context of the expansion of Iomab-B radioimmunotherapy for the treatment of leukemia, the change in the short-term debt-to-equity ratio demonstrates the ability of Actinium Pharmaceuticals (ATNM) to fund its clinical pipeline without a critical increase in credit leverage.